Хирургическое лечение и факторы прогноза у больных стромальными опухолями желудочно-кишечного тракта
Диссертация
При анализе показателей выживаемости у больных стромальными опухолями ЖКТ с KIT мутациями выявлено, что наилучшие результаты отмечались у больных с точечными заменами (независимо от локализации опухоли) и дупликациями в 11 экзоне KIT, хуже — у больных с делециями (независимо от локализации опухоли) и дупликациями в 9 экзоне KIT. Пятилетняя выживаемость у больных с точечными заменами KIT составила… Читать ещё >
Содержание
- 1. ГЛАВА 1 ОБЗОР ЛИТЕРАТУРЫ
- 1. 1. Морфологические особенности ГИСО
- 1. 1. 1. Гистологическая структура стромальных опухолей желудка
- 1. 1. 2. Гистологическая структура стромальных опухолей тонкой кишки
- 1. 1. 3. Гистологические особенности стромальных опухолей других локализаций
- 1. 1. 4. Морфологические факторы прогноза ГИСО
- 1. 2. Иммуногистохимические особенности стромальных опухолей ЖКТ
- 1. 3. Молекулярно — генетические характеристики ГИСО
- 1. 3. 1. Первичные KIT мутации
- 1. 3. 2. Первичные PDGFRA мутации
- 1. 3. 3. ГИСО синдромы 23″
- 1. 3. 4. Таргетная терапия ГИСО
- 1. 3. 5. Вторичные мутации, развивающиеся в процессе лечения тирозинкиназными ингибиторами
- 1. 3. 6. Диагностическое и прогностическое значение первичных KIT и PDGFRA мутаций
- 1. 4. Клиническая картина стромальных опухолей ЖКТ
- 1. 5. Современные подходы в лечении больных ГИСО
- 1. 5. 1. Лечение больных с местно-распространенными ГИСО
- 1. 5. 2. Лечение больных с метастатическими и рецидивными ГИСО
- 1. 1. Морфологические особенности ГИСО
- 2. 1. Методы исследования
- 2. 1. 1. Клинический анализ материала
- 2. 1. 2. Морфологическое исследование материала
- 2. 1. 3. Иммуногистохимическое исследование материала
- 2. 1. 4. Анализ мутационного статуса
- 2. 2. Общая характеристика больных
- 3. 1. Особенности клинической картины
- 3. 2. Особенности диагностики
- 4. 1. Характеристика больных с ГИСО, оперированных в других лечебных учреждениях
- 4. 2. Хирургическое лечение первичных больных с местно-распространенными стромальными опухолями ЖКТ
- 4. 2. 1. Непосредственные результаты хирургического лечения первичных больных с местно-распространенными стромальными опухолями ЖКТ
- 4. 2. 2. Интраоперационные осложнения
- 4. 2. 3. Послеоперационные осложнения
- 4. 2. 4. Отдаленные результаты хирургического лечения первичных больных с местно-распространенными стромальными опухолями ЖКТ
- 4. 3. Хирургическое лечение больных с метастатическими и рецидивными стромальными опухолями ЖКТ
- 5. 1. Макроописание
- 5. 2. Микроописание
- 5. 3. Иммуногистохимические характеристики ГИСО
Список литературы
- Анурова О. А Морфологическая и иммуногистохимическая диагностика гастроинтестинальных опухолей ЖКТ / Современная онкология. -экстра выпуск 2007.- Р 79−99.
- Анурова О.А. Морфологические характеристики Стромальных опухолей ЖКТ. / Снигур П. В., Филиппова Н. А., Сельчук В. Ю. // Архив патол. -2006.-Т. 268. -№ 1,-С. 10−13.
- Беляков И.С. Мутации генов c-Kit и PDGFRA и клинико-морфологические особенности стромальных опухолей желудочно-кишечного тракта. / О. А. Анурова, П. В. Снигур, И. В. Цыганова, В. Ю. Сельчук, Н. Н. Мазуренко. // Вопр. Онкол. 2007. Т 53, — № 6, — С. 677−81.
- Казанцева И.А. Морфологические особенности ГИСО / Современная онкология. экстра выпуск 2007. — Р. 50−79.
- Никулин М.П. //Гастроинтестинальные стромальные опухоли (ГИСО). Эпидемиология, диагностика, современные подходы к лечению. / Стилиди И. С. // Современная онкология. Экстра выпуск 2007. С. 3−50.
- Снигур П.В. Возможности иммуногистохимического метода в диагностике стромальных опухолей ЖКТ. / Анурова О. А., Филиппова Н. А. // Актуальные вопросы онкогастроэнтерологии. Материалы межрегионной научной конф. 6−7 июня 2003. Барнаул 2003. — Т-2, с-89−91.
- Снигур П.В. Клинико-морфологические особенности стромальных опухолей ЖКТ / Анурова О. А., Петровичев Н. Н., Сельчук В. Ю. // Вопросы онкологии 2003. — Т 49, — № 6, — С. 705−710.
- Снигур П.В. Стромальные опухоли желудочно-кишечного тракта. Клиника, диагностика, лечение. / Дис. канд. мед. наук. Москва 2004.
- Снигур П.В., Стромальные опухоли двенадцатиперстной кишки. / Анурова О. А. // Хирургия 2003. — № 11, — С. 46−48.
- Abbas Agaimy. Minute Gastric Sclerosing Stromal Tumors (GIST
- Tumorlets) Are Common in Adults and Frequently Show c-KIT Mutations. / Peter H.
- Wunsch, Ferdinand Hofstaedter, Hagen Blaszyk, Petra Rummele, Andrias Gaumann, 134
- Wolfgang Dietmaier, Arndt Hartmann. // Am. J. Surg. Pathol. 2007. Vol. 3, -P.113−120.
- Agaimy A. Minute gastric sclerosing stromal tumors (THCO tumorlets) are common in adults and frequently show c-KIT mutations. / Wunsch PH, Hofstaedter F // Am. J. Surg. Pathol. 2007. Vol. 31, — P. 113−120.
- Andersson J. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. / Bumming P, Meis-Kindblom JM // Gastroenterology 2006. -Vol. 130, P. 1573−1581.
- Andersson J. NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. / Sihto H, Meis-Kindblom JM // Am. J. Surg. Pathol. 2005- № 29- - P. 1170−1176.
- Andtbacka RH. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. / Ng CS, Scaife CL // Ann Surg Oncol 2007. № 14, -P. 14−24.
- Aparicio T. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. / Boige V, Sabourin JC // Eur J Surg Oncol 2004- -№ 30,-P. 1098−1103.
- Bauer S. Imatinib may enable complete resection in previously unresectable or metastatic GIST. / Hartmann JT, Lang H // Proc Am Soc Clin Oncol 2004- № 23, — P.819, abstract 9023.
- Bauer S. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase / AKT is a crucial survival pathway. / Duensing A, Demetri GD // Oncogene 2007- № 26- - P.7560−7568.
- Benjamin RS. for the Sarcoma Intergroup. Phase III dose-randomized study of imatinib mesylate (ST1571) for GIST: Intergroup S0033 early results. / Rankin C, Fletcher C // Proc Am Soc Clin Oncol 2003- № 22, — P. 814.
- Bertucci F. Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour. / Goncalves A, Monges G // Oncol. Rep. 2006- № 97- - P.97−101.
- Bonvalot S. Surgical treatment of GIST in the era of Gleevec. / Ann Chir 2005- № 130,-P.144−151.
- Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney triad): natural history, adrenocortical component, and possible familial occurrence. / Mayo Clin Proc 1999- № 74, — P.543- 52.
- Carney JA. The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. / Sheps SG, GoVL, Gordon H. N // Engl J Med 1977- № 296, — P. 1517 — 8.
- Chan P.M. Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. / Ilangumaran S, La Rose J., Chakrabartty A, Rottapel R. //Mol. Cell. Biol. 2003. Vol.23. — P.3067−3078.
- Chen H. Polyclonal nature of diffuse proliferation of interstitial cells of Cajal in patients with familial and multiple gastrointestinal stromal tumours. / Hirota S, Isozaki K. // Gut 2002. Vol. 51, — |P. 793−796.
- Chen LL. A missense mutation in KIT domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. / Trent JC, Wu EF // Cancer Res. 2004- № 64- - P.5913−5919.
- Cho S. Deletion of the KIT gene is associated with liver metastasis and poor prognosis in patients with gastrointestinal stromal tumor in the stomach. / Kitadai Y, Yoshida S //Int. J. Oncol. 2006. Vol. 28, — P. 1361−1367.
- Chompret A. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. / Kannengiesser C, Barrois M // Gastroenterology 2004- № 126- -P.318- 321.
- Corless CL, Biology of gastrointestinal stromal tumors. / Fletcher JA, Heinrich MC. // J. Clin. Oncol. 2004. Vol. 22, — P. 3813−3825.
- Corless CL. KIT gene deletion at the intron 10-exon 11 boundry in GI stromal tumors. / Mc Greevey L, Town A J. // Mol. Diag. 2004. Vol. 6, — P. 366 370.
- Corless CL. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. / Mc Greevey L, Haley A Am. // J. Pathol. 2002. Vol. 160- 1567−1572.
- Corless CL. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. / Schroeder A, Griffith D // J. Clin. Oncol. 2005. Vol. 23, — P. 5357−5364.
- Corless CL. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. / Schroeder A, Griffith D // J. Clin. Oncol. 2005. № 23. — P.5357−5364.
- Corless CL. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. / Schroeder A, Griffith D // J. Clin. Oncol. 2005- № 23- - P. 5357−5364.
- Crosby J.A. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. / Catton C. N, Davis // A. Ann Surg Oncol 2001- -Vol.8: P.50−9.
- De Matteo R. P Clinical management of gastro-intestinal stromal tumors: before end after STI-571 / Heinrich M. C, El-Rifai W.M. // Hum. Patho. J.- 1999. № 30,-P. 1213−20.
- Debiec-Rychter M. Mechanisms of resistence to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinibresistant mutants. / Cools J, Dumez H. // Gastroentereology 2005. Vol. 128, — P. 270−279.
- Demetri G.D. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. / von Mehren M, Blanke C.D.N. // Engl. J. Med. 2002. Vol.347, — P.472−80.
- Demetri GD. Identification and treatment of chemoresistant inoperable or metastatic THCO: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). / Eur. J. Cancer 2002- Vol. 38 (Suppl. 5) — - P.52-S59.
- Duensing A. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumours (rHCOs). / Medeiros F, Mc Conarty B. // Oncogene 2004. Vol. 23, -P. 3999^1006.
- Eisenberg BL. Combining imatinib mesylate with surgery for patients with gastrointestinal stromal tumors: Rationale and ongoing trials. / Monographs in Gastrointestinal Stromal Tumors 2004- Vol.1- - № 1 and 2, — P. 9−14.
- Eisenberg BL. Surgery and imatinib in the management of GIST: Emerging approaches to adjuvant and neoadjuvant therapy. / Judson I. // Ann Surg Oncol 2004- № 11, -P. 465175.
- Ernst SI. KIT mutation portends poor prognosis in gastrointestinal stromal /smooth muscle tumors. / Hubbs AE, Przygodzki RM // Lab. Invest. 1998- -№ 78- P.1633−1636.
- Feng F. Expression and mutation of c-kit gene in gastrointestinal stromal tumors. / Liu XH, Xie Q. // World J. Gastroenterol. 2003. T. 9, — P. 2548−2551.
- Fletcher J. A, Mechanisms of resistance to imatinib mesylate in advanced gastrointestinal stromal tumors. / Corless C. L, Dimitrijevic S.Proc. // Am. Soc. Clin. Oncol. 2003- Vol.22: — P.815 (A3275).
- Fletcher JA. Role of KIT and platelet-derived growth factor receptors as oncoproteins. / Semin. Oncol. 2004. Vol. 31, — Suppl. 6, — P. 4−11.
- Gronchi A. Surgeiy of residual disease following imatinib mesylate iniadvanced gastrointestinal stromal tumors (GIST). / Fiore M, Bertulli R // J Clin Oncol 2005- Suppl, 2005 ASCO Annual Meeting Proceedings, — 825s- abstract 9038.
- Gupta M. Outcome following surgical therapy for gastrointestinal stromal tumors. / Sheppard BC, Corless CL // J Gastrointest Surg 2006, № 0: -P.1099−1105.
- Haller F. Site-dependent differential KIT and PDGFRA expression in gastric and intestinal stromal tumors. / Happel N, Schulten H-J // Mod. Pathol. 2007, -Vol. 20,-P. 1103−1111.
- Haller F. Site-dependent differential KIT and PDGFRA expression in gastric and intestinal stromal tumors. / Happel N, Schulten H-J // Mod. Pathol. 2007- № 20- - P. 1103−1 111.
- Haller F. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. / Detken S, Schulten HJ // Ann. Surg. Oncol. 2007- -№ 14- P.526−532.
- Hartmann K. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. / Wardelmann E, Ma Y // Gastroenterology 2005- № 129- - P. 1042−1046.
- He HY. c-kit and PDGFRS mutations in 60 cases of gastrointestinal tumors (THCOs). / Xiang YN, Zhong HH Beijing // Da Xue Xue Bao 2005. Vol. 37, — P. 320−324.
- Heinrich M.C. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. / Corless C. L, Demetri G.D. // J. Clin. Oncol. 2003- Vol.21: — P.4342- 9.
- Heinrich MC. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. / Corless CL, Blanke CD // J. Clin. Oncol. 2006- -№ 24- P.4764−4774.
- Heinrich MC. PDGFRA activating mutations in gastrointestinal stromal tumors. / Corless CL, Duensing A // Science 2003. Vol. 299, — P. 708−710.
- Hirota S, Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. / Nishida T, Isozaki K // J. Pathol. 2001. Vol. 193,-P. 505−510.
- Hirota S. Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene. / Okazaki T, Kitamura Y Am. // J. Surg. Pathol. 2000- № 24- - P.326−327.
- Hirota S. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. / Nishida T, Isozaki K // Gastroenterology 2002- -№ 122- P. 1493−1499.
- Hirota S. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. / Ohashi A, Nishida T // Gastroenterology 2003- № 125- - P.660−667.
- Hopkins T.G. Sunitinib in the management of gastrointestinal stromal tumours (GISTs). / J. Marples M, D. Stark. // Cane. Surg. 2008. Vol.34, — P. 844 850.
- Hopkins T.G., Sunitinib in the management of gastrointestinal stromal tumours (GISTs). / M. Marples*, D. Stark // EJSO 2008. — № 34, — P. 844 — 850.
- Hostein I, Detection of a new mutation in KIT exon 9 in a gastrointestinal stromal tumor. / Longy M, Gastaldello B // Int. J. Cancer 2006- -№ 118-- P.2089−2091.
- Hostein I. Detection of a new mutation in KIT exon 9 in a gastrointestinal stromal tumor. / Longy M, Gastaldello B // Int. J. Cancer 2006- № 118- - P.2089−2091.
- Huizinga J.D. Gastrointestinal peristalsis: joint action of enteric nerves, smooth muscle, and interstitial cells of Cajal. / Microsc. Res. Tech. 1999- Vol.47- -P.239−247.
- Isozaki K. Germline-activating mutation in the kinase domain on KIT gene in familial gastrointestinal stromal tumors. / Terris B, Belghiti J Am. // J. Pathol. 2001--№ 157- -P.1581−1585.
- Joensuu H. Effect of tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. / Roberts PJ, Sarlomo-Rikala M. // Engl. J. Med. 2001. Vol. 344, — P. 1052−1056.
- Kang DY. Multiple gastrointestinal stromal tumors: clinicopathologic and genetic analysis of 12 patients. / Park CK, Choi JS // Am. J. Surg. Pathol. 2007- -№ 31- P.224−232.
- Kang H.J. Correlation of KIT and platelet derived growth factor receptor a mutations with gene activation and expression profiles in gastrointestinal stromal tumors. / Nam SW, Kim H // Oncogene 2005. T 24, — P. 1066−1074.
- Kemmer K. KIT mutations are common in testicular seminomas. / Corless CL, Fletcher JA. // Am. J. Pathol. 2004. — № 164, — P. 305−313.
- Kikuchi H. Immunohistochemical and genetic features of gastric and metastatic liver gastrointestinal stromal tumors: sequential analyses. / Yamashita K, Kawabata T // Cancer Sci. 2006- № 97- - P. 127−132.
- Kim TW. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. / Lee H, Kang Y-K // Clin. Cancer Res. 2004- № 10- -P. 3076−3081.
- Kinoshita K. Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients. / Hirota S, Isozaki K // J. Pathol. 2004- № 202- - P. 80−85.
- Lasota J, Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of two hundred cases. / Wozniak A, Sarlomo-Rikala M // Am. J. Pathol. 2000- Vol. 157, — P. 1091−1095.
- Lasota J. A great majority of GISTs with PDGFRA mutations represents gastric tumors of low or no malignant potential. / Dansonka-Mieszkowska A, Sobin LH. //Lab. Invest. 2004- № 84- -P. 874−883.
- Lasota J. A great majority of THCOs with PDGFRA mutations represents gastric tumors of low or no malignant potential. / Dansonka-Mieszkowska A, Sobin LH // Lab. Invest. 2004- № 84- - P. 874−883.
- Lasota J. A new familial GIST identified. / Miettinen M. // Am. J. Surg. Pathol. 2006- № 30- - P. 1342.
- Lasota J. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primaiy KIT exon 13 or exon 17 mutations. A multi-center study on 54 cases. / Corless CL, Heinrich MC // Mod. Pathol. 2008. Epub ahead of print.
- Lasota J. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations. A multi-center study on 54 cases. / Corless CL, Heinrich MC // Mod. Pathol. 2008- Epub ahead of print.
- Lasota J. GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. / Stachura J, Miettinen M.Lab.// Invest. 2006- № 86- - P.94−100.
- Lasota J. KIT and PDGFRA mutations in gastrointestinal stromal tumors (THCOs). / Miettinen M. // Semin. Diagn. Pathol. 2006. Vol. 23, — P. 91−102.
- Lasota J. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. / Jasinski M, Sarlomo-Rikala M 1. // Am. J. Pathol. 1999. — № 154,-P. 53−60.
- Lasota J. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. / Jasinski M, Sarlomo-Rikala M // Am. J. Pathol. 1999- № 154- -P.53−60.
- Lasota J.- Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. / Miettinen M.: Department of Soft Tissue Pathology, Armed Forces Institute of Pathology, Washington DC. USA Histopathology 2008. — P. 4−16.
- Li FP. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. / Fletcher JA, Heinrich MC // J. Clin. Oncol. 2005- -№ 23- P.2735−2743.
- Longley BJ. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. / Tyrrell L, Lu S-Z / Nat. Genet. 1996- № 12- - P.312−314.
- Lux ML, KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. / Rubin BP, Biase TL // Am. J. Pathol. 2000. Vol. 156,-P. 791−795.
- Ma Y, Cunningham M. Inhibition of spontaneous receptor phosphorylation by residues in putative alpha-helix in the KIT intracellular juxtamembrane region. / Wang X, Ghosh I, Regan L, Longley B. // Biol. Chem. 1999. Vol.274, — P. 13 399−13 402.
- Miettinen M, Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. El-Rifai W, L HLS // Hum Pathol 2002, № 33, -P. 478 483.
- Miettinen M. Gastrointestinal stromal tumors (GISTs) of the stomach—a clinicopathologic, immunohistochemical and molecular genetic study of 1756 cases with long-term follow-up. / Sobin LH, Lasota J. // Am. J. Surg. Pathol. 2005- № 29-- P.52−68.
- Miettinen M. Gastrointestinal stromal tumors (rHCOs): definition, occurrence, pathology, differential diagnosis and molecular genetics / Lasota J. // Pol. J. Pathol. 2003. — № 54, — P. 3−24.
- Miettinen M. Gastrointestinal stromal tumors definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. / Lasota J // Virchows Archiv 2001. № 438: — P. 1−12.
- Miettinen M. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. / Fetsch JF, Sobin LH// Am. J. Surg. Pathol. 2006- -№ 30- P.90−96. 80.
- Miettinen M. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic studies of 1765 cases with long-term follow-up. / Sobin LH, Lasota J. // Am J. Surg. Pathol. 2005. Vol.29, — P.52−68.
- Miettinen M. Gastrointestinal Stromal Tumors. Review on Morphology, Molecular Pathology, Prognosis, and Differential Diagnosis / Lasota J. // Arch. Pathol. Lab. Med. 2006. —№ 130, — P. 1466 — 1476.
- Min K.W. Interstitial Cells of Cajal (ICC) and Gastrointestinal Stromal Tumor (THCO): facts, speculations, and myths. / Leabu M.J. // Cell. Mol. Med. -2006. T 10, — № 4, — P. 995−1013.
- Miselli F. C-KIT/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. / Casieri P, Negri T // Clin. Cancer Res. 2007- 13- 2369−2377.
- Mol CD. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. / Dougan DR, Schneider TR J. Biol. // Chem. 2004. Vol. 279, -P. 31 655−31 663.
- Morabito A. Clinical benefit of intermittent administration of imatinib in a patient with metastatic gastrointestinal stromal tumour. / Longo R, Carilio G // Clin Oncol 2005- № 17, — P.96−97.
- Mudan S.S. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selectiaon. / Conlon K. C, Woodruff J.M. // Cancer 2000- -Vol.88, P.66−74.
- Neuhaus SJ. Surgeiy for gastrointestinal stromal tumour in the post-imatinib era. / Clark MA, Hayes AJ ANZ // J Surg 2005- № 75, — P. 165−172.
- Nishida T, Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. / Hirota S, Taniguchi M Nat. // Genet. 1998- -№ 19- -P.323−324.
- Pauls K. PDGFRa and c-kit mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features. / Merkelbach-Bruse S. // Thai D Histopathology 2005. — Vol. 46, — P. 166 175.
- Pauls K. PDGFRa- and c-kitmutated gastrointestinal stromal tumours (THCOs) are characterized by distinctive histological and immunohistochemicalfeatures. / Merkelbach-Bruse S, Thai D // Histopathology 2005- № 46- - P.166−175.
- Pawlik TM. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. / Vauthey JN, Abdalla EK // Arch Surg 2006, № 141, P.537−543.
- Pawson T. Regulation and targets of receptor tyrosine kinases. / Eur. J. Cancer 2002. Vol. 38. — P. 3−10.
- Penzel R. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated. / Aulmann S, Moock M. // J. Clin. Pathol. 2005- № 58- - P. 634−639.
- Pierie J.P. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. / Choudry U, Muzikansky A, Yeap B. Y, Souba W. W, Ott MJ. // Arch. Surg. 2001. Vol.136, — P.383−9.
- Robson ME. Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. / Glogowski E, Sommer G // Clin. Cancer Res. 2004- № 10- - P.1250−1254.
- Rubin B.P. Gastrointestinal stromal tumour. / Heinrich M. C, Corless // C.L.Lancet 2007. Vol.368, — P. 1731−1741.
- Rubin BP, KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001 / Singer S., Tsao C. // № 61, — P. 8118−8121. 7.
- Rubin BP. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. / Singer S, Tsao C // Cancer Res. 2001- № 61- - P.8118−8121.
- Rutkowski P. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. / Nowecki Z, Nyckowski P // J Surg Oncol 2006, № 93, -P. 304−311.
- Sakurai S. Myxoid epithelioid gastrointestinal stromal tumor (THCO) with mast cell infiltrations: a subtype of THCO with mutations of platelet-derived growth factor receptor alfa gene. / Hasegawa T, Sakuma Y // Human Pathol. 2004- -№ 35- P.1223−1230.
- Scaife CL. Is there a role for surgery in patients with «unresectable» cKIT gastrointestinal stromal tumors treated with imatinib mesylate? / Hunt KK, Patel SR Am J Surg 2003- № 186, — P. 665−669.
- Taniguchi M. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. /Nishida T, Hirota S // Cancer Res. 1999- № 59- - P.4297−4300.
- Tarn C. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. / Merkel E, Canutescu AA // Clin. Cancer Res. 2005- -№ 11-- P.3668−3677.
- Tarn C. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. / Skorobogatko YV, Taguchi T, Eisenberg B, von Mehren M, Godwin AK. // Cancer Res. 2006- № 66- -P.5477—5486.
- Tuveson DA. STI571 inactivation of the gastrointestinal stromal c-KIT oncoprotein: biological and clinical implications. / Willis NA, Jacks T // Oncogene 2001- № 20- - P.5054−5058.
- Verweij J. Progression free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. / Casali P. G, Zalcberg J. // Lancet 2004, -Vol.364,-P. 1127−34.
- Wakai T. Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with second KIT mutation. / Kanda T, Hirota S // Br. J. Cancer 2004- № 90- - P.2059−2061.
- Wardelmann E. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. / Thomas N, Merkelbach-Bruse S //Lancet Oncol. 2005- -№ 6- P.249−251.
- Wardelmann E. c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant. / Neidt I, BierhoffE. //Mod. Pathol. 2002- Vol.15- -P.125−136.
- Wardelmann E. c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant. / Neidt I, Bierhoff E // Mod. Pathol. 2002- № 15- - P.125−136.
- Wardelmann E. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. / Merkelbach-Bruse S, Pauls K // Clin. Cancer Res. 2006- № 12- - P.1743−1749.
- Williams DE. Identification of a ligand for the c-kit protooncogene. / Eisenman J, Baird A // Cell 1990. Vol. 63, — P. 167−174.
- Yantiss R. et al. Multiple gastrointestinal stromal tumors in type I neurofibromatosis: a pathologic and molecular study. / Rosenberg AE, Sarran L // Mod. Pathol. 2005- № 18- -P.47584.